Abstract: The present specification discloses one or more anti-oncogenic phytochemicals comprising one or more compounds of chemical formula I: wherein R1is independently selected from H, CH3 or C2H5or is not present; R2 is independently selected from H, CH3 or C2H5 or is not present; provided that when R1 is not present, R2 is selected from H, CH3 or C2H5 and when R2 is not present R1 is selected from H, CH3 or C2H5: R3 is a C4-40 straight or branched chain, alkyl or alkylene and optionally substituted with one or more groups independently selected from CH3, OH, SH, NH2, OMe, OEt, N(H)Me and NMe2; and X is independently selected from CH3, OH, SH, NH2, OMe, OEt, N(H)Me, and NMe2, as well as, extracts, pharmaceutical compositions and medicaments comprising the one or more anti-oncogenic phytochemicals disclosed herein, methods of preparing such extracts, pharmaceutical compositions, and medicaments comprising the one or more anti-oncogenic phytochemicals , and methods and uses for treating a neoplasm or a cancer usi

Abstract: The present invention describes specific biocidally effective preservative mixtures and aqueous polymer solutions stabilized with these preservative mixtures and their use in cosmetic preparations, such as skin care and hair care compositions, and hairstyling products and in products for the home care sector.

Abstract: Use of benzyl alcohol as a defoaming agent and an antimicrobial agent in an oral care composition including a surfactant. Also described is a method of manufacturing an oral care composition including forming an oral care base composition, subsequently combining the oral care base composition with a defoaming agent and at least one surfactant to form the oral care composition; and defoaming the oral care composition. The surfactant is combined with the oral care base composition no later than the defoaming agent. The defoaming agent is benzyl alcohol.

Abstract: Provided herein are methods for prevention and treatment of ischemia-reperfusion (IR) injury in the cardiac myocytes of a subject, by administration to the subject, a compound of formula I, or a salt, solvate, or stereoisomer thereof, in a sufficient amount either prior to, or during and/or after an ischemic event to mitigate or prevent IR injury to the cardiac tissue. Pharmaceutical compositions including the compound of formula I, or a salt, solvate, or stereoisomer thereof, and/or at least one additional therapeutic agent, are also provided.

Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.

Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.

Abstract: The present invention relates to the use of at least one dicyclohexylmethanol derivative of the formula (I) as antimicrobial active compound or as anti-acne, antidandruff, deodorant or antiperspirant active compound, to preparations comprising these compounds, and to specific dicyclohexylmethanol derivatives and to a process for the preparation thereof.

Abstract: The present invention relates to the use of at least one cyclohexanol ether derivative of the formula I as antimicrobial active compound or as anti-acne, antidandruff, deodorant or antiperspirant active compound, to preparations comprising these compounds, and to specific cyclohexanol ether derivatives.

Abstract: The present invention relates to a novel use of sesquiterpenoid compounds, the pharmaceutically acceptable salts thereof, or the extracts of Cyperus rotundus comprising same or the fractions thereof in the prevention or treatment of menopausal diseases. The sesquiterpenoid compound according to the present invention, the extracts of Cyperus rotundus comprising the same or fractions thereof exhibit excellent estrogenic activity or anti-allergic activity, and therefore they can be used for the prevention or treatment of menopausal diseases caused by a decline in estrogen level or by allergic diseases.

Abstract: The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone.

Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Abstract: This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

Abstract: A compound having formula I. R1, R2, R3 and R4 are independently H or lower alkyl. R5 is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, arylamino, heteroarylamino, cycloalkylamino, heterocycloalkyl amino, arylthio, heteroarylthio, cycloalkylthio, heterocycloalkylthio, or cyclic olefin, any of which may be substituted or non-substituted; or substituted alkyl, substituted alkyl oxy or substituted alkyl amino wherein the substituent is an aryl, a heteroaryl, a cycloalkyl, a heterocycloalkyl or a cyclic olefin, any of which may be substituted or non-substituted. X is C or N. n and p are independently whole numbers selected from 0, 1 and 2. (CH2)n and (CH2)p may be substituted or non-substituted. Ar1 and Ar2 are independently aryl or heteroaryl groups which may be substituted or non-substituted. Certain specific compounds are excluded.

Abstract: The present application provides terpene analogues of Formula 1 and methods and uses thereof for treating neurological conditions such as pain in general and neuropathic pain specifically. wherein: Y is a C1 to C20 alkylene, C?O, SO, SO2, or absent; X is H, OR1, N—(R2)2, a C1 to C20 alkyl, or a heterocyclyl (for example, heteroaryl), wherein when Y is absent X is not H; R1 is H, a C1 to C20 alkyl, or a CH2-aryl; R2 is independently H, a C1 to C20 alkyl, aryl, OR1, CN or C(?O)—R3; R3 is a substituted or unsubstituted C1 to C20 alkyl, or a aryl; W is H, C1 to C20 alkyl, or aryl; and Z is C1 to C20 alkylene; or a pharmaceutically acceptable isomer, salt or ester thereof. These terpene analogues are useful in treating pain and can also be used to treat other electrical disorders in the central and peripheral nervous system.

Abstract: The present invention provides an essential oil containing cineole for eliciting tomato resistance to disease by fungal infection. The present invention also provides a method to elicit tomato resistance to disease by fungal infection.

Abstract: Compounds are provided herein which are coordination complexes of the formula, AxByCit2Fz.mH2O, wherein A is a cation selected from certain IA or IIA metal ions in the Periodic Table; B is a cation selected from certain IIA metal ions and certain divalent d-block transition metal ions; A and B are different; “Cit” is tribasic citric acid anion; the stoichiometric ratio of x to y is equal or higher than 1.0 but lower than 8.0; m is 0-12; and z is selected such that electroneutrality is preserved. Compounds provided herein are useful to treat dietary deficiencies, osteoporosis, osteopenia, bone loss, and risk of bone loss, as well as other medical conditions involving the need for administration of the various ions. In addition, the compounds can be used as fluoride sources for dental use and to fluoridate water systems.

Abstract: A stabilizer composition having (a) one or more 1- or 2-(C1- to C24-alkyl) glycerol ethers (glycerol monoalkyl ethers) and (b) a mixture of at least two different aromatic alcohols (b1, b2) chosen from the groups of i) aryloxyalkanols, ii) arylalkanols and iii) oligoalkanol aryl ethers, where the two different aromatic alcohols belong to different groups i), ii) and iii).

Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.

Abstract: A fire ant killer chemical composition (the “FAK Composition”) for effective killing of fire ants where the FAK Composition utilizes a minimal amount of active ingredients thereby significantly reducing safety concerns with respect to the use of said active ingredients, the FAK composition having a dish detergent composition and an insecticide composition.

Abstract: The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.

Abstract: A compound having formula I. R1, R2, R3 and R4 are independently H or lower alkyl. R5 is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, arylamino, heteroarylamino, cycloalkylamino, heterocycloalkyl amino, arylthio, heteroarylthio, cycloalkylthio, heterocycloalkylthio, or cyclic olefin, any of which may be substituted or non-substituted; or substituted alkyl, substituted alkyl oxy or substituted alkyl amino wherein the substituent is an aryl, a heteroaryl, a cycloalkyl, a heterocycloalkyl or a cyclic olefin, any of which may be substituted or non-substituted. X is C or N. n and p are independently whole numbers selected from 0, 1 and 2. (CH2)n and (CH2)p may be substituted or non-substituted. Ar1 and Ar2 are independently aryl or heteroaryl groups which may be substituted or non-substituted. Certain specific compounds are excluded.

Abstract: A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level.

Abstract: An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ?99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam stabilizer, e) optionally, at least one member selected from the group consisting of cosmetic auxiliaries, adjuvants, active ingredients, and mixtures thereof, and f) optionally water. The surface tension of component b) lies in the range of ±15 dyn/cm of the surface tension of component a) or corresponds to the surface tension of component a), and the sum of components a) to f) is 100 wt % relative to the total quantity of the foam composition.

Abstract: The invention provides a means capable of effectively inactivating and removing allergen or a precursor thereof. The invention relates to an allergen-reducing agent containing water and a water-soluble polymer compound having units having hydroxy or carboxy groups wherein at least a part of hydrogen atoms of the hydroxy or carboxy groups are substituted by specific groups containing a polyether group.

Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.

Abstract: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Abstract: A preparation for creating a clearing feeling in a pharyngeal cavity and nasal cavity comprising a rhinologically active substance of formula (I): In formula (I), variable x and substituents R1, R2 and R3 have the following meanings: x is 0 or 1, R1 denotes an alkyl group having 1 to 4 carbon atoms, R2 denotes a methyl or ethyl group, and R3 denotes a monocyclic saturated carbon system having 5, 6, 7 or 8 carbon atoms that can be unsubstituted or substituted with further alkyl groups having 1 to 4 carbon atoms or alkenyl groups having 2 to 4 carbon atoms. The compound of formula (I) can be mixed with one or more other flavor substances or aroma substances. The preparation can be an oral care composition, such as a toothpaste or a mouth wash.

Abstract: Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.

Abstract: The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.

Abstract: The present invention provides an essential oil containing cineole for eliciting tomato resistance to disease by fungal infection. The present invention also provides a method to elicit tomato resistance to disease by fungal infection.

Abstract: The invention provides novel 1,2-diphenylethene derivatives and pharmaceutically acceptable salts thereof, the process for production of these compounds and their pharmaceutical composition and the use of these compounds as modulators of T-cells, neutrophils, macrophages and their associated cytokines as agents for treating immune, inflammatory and auto-immune diseases.

Abstract: Disclosed herein are ways to solubilize aspirin for parenteral administration containing aspirin and a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of acute coronary syndromes as well as other disease states. The solution so constituted is stable at room temperature for prolonged periods without decomposition and avoids significant hydrolysis of the aspirin and thus the loss of the anti-platelet action when stored.

Abstract: Methods of inhibiting the onset and progression of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis are provided. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. Also provided are methods of treating or preventing Alzheimer's disease or MCI that involve the use of such compositions. Also provided are methods of using D-pinitol to promote a healthy nervous system and as a food supplement.

Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.

Abstract: The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

Abstract: The present invention provides a substance which promotes the transdermal absorption of a pharmacologically active component while little irritating the skin. The present invention relates to a transdermal absorption promoter which comprises, as the active component, at least one member selected from among isopulegol, 2-(menthoxy)ethanol and 2-methyl-3-(menthoxy)propane-1,2-diol; and an external skin formulation which comprises a pharmacologically active component such as a psychotropic component, an anti-inflammatory component, an analgesic component, an antipyretic component, a whitening component or a hair growth-promoting component, together with the aforesaid transdermal absorption promoter.

Abstract: The objective of the present invention is to provide an antimicrobial composition that can be safely used with a broad range of foods and beverages, cosmetics, drugs, and other similar products while showing growth inhibition activity against a wide variety of microorganisms. The present invention relates to the antimicrobial composition comprising at least one cooling agent selected from the group consisting of menthyl 3-hydroxybutanoate, 2-methyl-3-(menthoxy)propane-1,2-diol, 2-(menthoxy)ethanol, 3-menthoxypropan-1-ol, 2-(2-menthoxyethoxy)ethanol, and menthyl glyoxylate.

Abstract: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.

Abstract: Provided are a triterpene derivative represented by a general formula (I), a pharmaceutically acceptable salt thereof, and an agent for preventing or treating chronic hepatitis C comprising the triterpene derivative or the salt as an active ingredient: [in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or and R2 represents —OR3 or —O— (CH2) m-OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is —CH2OH, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].

Abstract: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.

Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma and liver tissue, blood glucose and blood insulin levels in a fast state, finally exhibiting efficacies on prevention or treatment of hyperlipidemia, fatty liver, diabetes and obesity.

Abstract: A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising an encapsulated active contained in a matrix material, an encapsulated active comprising at least one nano-particle encapsulated in a micro-particle, wherein said nano-particle comprises a shell comprising a hydrophobic material, and wherein said micro-particle comprises a shell comprising a water sensitive material; and wherein at least one of said nano-particle and said micro-particle comprises a skin care active.

Abstract: The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.

Abstract: An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ?99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam stabilizer, e) optionally, at least one member selected from the group consisting of cosmetic auxiliaries, adjuvants, active ingredients, and mixtures thereof, and f) optionally water. The surface tension of component b) lies in the range of ±15 dyn/cm of the surface tension of component a) or corresponds to the surface tension of component a), and the sum of components a) to f) is 100 wt % relative to the total quantity of the foam composition.

Abstract: Disclosed are a pest control agent, a method for preparing a pest control agent, and a method for controlling a pest. Generally, the pest control agent is formed by providing a porous starch and an active control agent absorbed within the porous starch, and compressing the porous starch in the presence of heat to form discrete plural particles. Preferably, one or more binders are employed, as are one or more secondary absorbents/fillers. In highly preferred embodiments of the invention, the pest control agent is prepared via pelletizing in a commercial pellet mill. The particles so prepared should be sufficiently durable to withstand bulk transport, such as by rail car or bag shipment. The particles should, however, release the control agent quickly upon contact with water, such that, for instance, the control agent may be released when the pest control agent is introduced to standing water. It is contemplated that the control agent is preferably a mosquito control agent.

Abstract: A method of controlling microorganisms such as lactobacilli metabolism in mash in an ethanol production facility includes adding to the mash an effective amount to control such microorganisms of one or more of a substantially water insoluble pristinamycin-type antimicrobial agent, a substantially water insoluble polyether ionophore antimicrobial agent, or both, wherein the term “substantially water insoluble” means the antimicrobial agent has a solubility in pure water at 20° C. of 0.

Abstract: An objective of the present invention is to provide a composition that has improved oral absorption and comprises a slightly soluble drug, and to provide a process for producing the same. According to the present invention, there is provided a finely pulverized composition comprising a slightly soluble drug such as 22?-methoxyolean-12-ene-3?, 24(4?)-diol and a hydrophilic surfactant. According to the present invention, there is also provided a process for producing the finely pulverized composition according to the present invention, characterized in that, after the dispersion of a slightly soluble drug and a hydrophilic surfactant in a solvent, the dispersion is pulverized with a high-pressure homogenizer.

Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.

Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.